- Home
- BMA vs NUVL Comparison
BMA vs NUVL Comparison
Compare BMA & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMA
- NUVL
- Stock Information
- Founded
- BMA 1966
- NUVL 2017
- Country
- BMA Argentina
- NUVL United States
- Employees
- BMA N/A
- NUVL N/A
- Industry
- BMA Commercial Banks
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- BMA Finance
- NUVL Health Care
- Exchange
- BMA Nasdaq
- NUVL Nasdaq
- Market Cap
- BMA 6.3B
- NUVL 5.6B
- IPO Year
- BMA 2006
- NUVL 2021
- Fundamental
- Price
- BMA $76.85
- NUVL $70.46
- Analyst Decision
- BMA Hold
- NUVL Strong Buy
- Analyst Count
- BMA 3
- NUVL 10
- Target Price
- BMA $50.83
- NUVL $113.10
- AVG Volume (30 Days)
- BMA 269.7K
- NUVL 594.2K
- Earning Date
- BMA 05-21-2025
- NUVL 05-08-2025
- Dividend Yield
- BMA 6.91%
- NUVL N/A
- EPS Growth
- BMA N/A
- NUVL N/A
- EPS
- BMA 0.49
- NUVL N/A
- Revenue
- BMA $4,443,772,797.00
- NUVL N/A
- Revenue This Year
- BMA N/A
- NUVL N/A
- Revenue Next Year
- BMA $5.76
- NUVL N/A
- P/E Ratio
- BMA $19.08
- NUVL N/A
- Revenue Growth
- BMA N/A
- NUVL N/A
- 52 Week Low
- BMA $42.23
- NUVL $61.80
- 52 Week High
- BMA $118.42
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- BMA 40.79
- NUVL 39.36
- Support Level
- BMA $73.05
- NUVL $67.47
- Resistance Level
- BMA $77.89
- NUVL $77.93
- Average True Range (ATR)
- BMA 3.82
- NUVL 3.15
- MACD
- BMA -0.14
- NUVL -0.44
- Stochastic Oscillator
- BMA 26.93
- NUVL 26.88
About BMA Banco Macro S.A. ADR (representing Ten Class B)
Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. It generates the majority of its revenue from Argentina.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.